[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-mass\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-mass":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,76,105,143,175,210,243,264],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100608713","a-randomized-controlled-trial-comparing-whole-body-vibration-therapy-with-usual-care-and-usual-care-to-improve-muscle-health-in-older-adults-100608713",false,"NCT07205133","A Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle Health in Older Adults","Effectiveness of Whole Body Vibration Therapy and Usual Care Compared to Usual Care in Improving Muscle Mass, Strength and Function in Older Adults","Inclusion Criteria:\n\n* Healthy Volunteer or Patients aged 65 and above,\n* Clinical frailty Scale (CFS) score of 3-4,\n* Independently ambulating without any aid\n* willingness and consent to participate in the study and ability to travel to the study-site for the measurements and interventions, and\n* participants with no regular exercise habits (defined as less than 150mins\u002Fweek of moderate intensity aerobic exercise and less than twice a week of strengthening exercises)for past 3 months.\n\nExclusion Criteria:\n\n* current active enrolment into any Day Rehab or community exercise program,\n* contraindications to WBVT machine usage (see below),\n* diagnosis of dementia,\n* history of Diabetes Mellitus\n* BMI ≤20kg\u002Fm2,\n* recent hospital admissions within the last 3 months,\n* end stage organ failure,\n* chronic diseases which are not well managed, for example, poorly controlled hypertension,\n* New York Heart Association (NYHA) score II and above for patients with history of heart failure and\n* MUST Score ≥1.\n\nContraindications to WBVT:\n\nPRIMARY CONTRAINDICATIONS TO WBVT\n\n* Pregnancy\n* Acute thrombosis (acute vascular occlusion)\n* Artificial joints in stimulated body regions\n* Fresh fractures in stimulated body regions\n* Within 3 months post surgery\u002Fprocedure and\u002For any fresh wounds and scars in the stimulated body regions\n* or if the wound healing is not yet completely finished.\n\nSECONDARY CONTRAINDICATIONS TO WBVT\n\n* Acute inflammation of the musculoskeletal system, activated arthrosis or\n* arthropathy (e.g. acute inflammation and swelling in joints).\n* Acute tendinopathies in stimulated body regions (acute tendonitis)\n* Acute hernias (tissue ruptures)\n* Acute discopathy (acute disc-related back problem)\n* Stone disease of the bile ducts and urinary tract\n* Rheumatoid Arthritis\n* Epilepsy due to secondary risk of injury",true,"ALL","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a randomized controlled trial where participants would be randomly assigned to one of 2 groups. One group would receive Whole body vibration therapy and usual care and the other group only usual care. Measurements of muscle mass, strength and function would be taken before the interventions, and at 2 other points after interventions. Differences in the outcomes between the two groups would be analysed.",[27,28,29,30,31,32],"Aging","Frailty","Sarcopenia","Muscle Strength","Muscle Function","Muscle Mass",[27,28,29,34,30,31,32],"Whole Body Vibration Therapy","RECRUITING","2026-04-14",{"date":38,"type":39},"2026-04-15","ACTUAL",{"date":41,"type":39},"2026-01-10",{"date":43,"type":21},"2027-03-31",{"name":45,"class":46},"Changi General Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100630205","ems-combined-with-resistance-training-in-weight-lifters-100630205","NCT07484646","EMS Combined With Resistance Training in Weight Lifters","Effects of Electrical Muscle Stimulation Combined With Resistance Training on Muscle Mass, Strength, Body Composition, and Power in Weight Lifters","Inclusion Criteria:\n\n* Male participants aged 18-40 years\n* Resistance training ≥3 times\u002Fweek for at least 1 year\n* Active participation in weightlifting, bodybuilding, or strength athletics\n* Medically cleared for physical activity\n\nExclusion Criteria:\n\n* Neuromuscular disorders\n* Cardiac pacemaker or implantable electronic device\n* Recent musculoskeletal injury (within the last 6 months)\n* Skin sensitivity or allergy to EMS electrodes","MALE","18 Years","40 Years",{"count":59,"type":21},34,[24],"The purpose of this randomized controlled trial is to determine the effects of Electrical Muscle Stimulation (EMS) combined with resistance training on muscle mass, muscular strength, body composition, and power in trained weightlifters. Participants will be randomly allocated into two groups: one receiving resistance training alone and the other receiving EMS combined with resistance training. The intervention will be conducted for eight weeks, and outcome measures will be assessed at baseline, mid-intervention (4 weeks), and post-intervention (8 weeks). The findings of this study may provide evidence regarding the additional benefits of EMS when combined with conventional resistance training programs in enhancing muscular performance among trained athletes.",[63,32,30],"Body Composition",[32,30,63,65,66],"Resistance Training","Electrical Muscle Stimulation","2026-03-16",{"date":69,"type":39},"2026-03-20",{"date":71,"type":39},"2025-12-01",{"date":73,"type":21},"2026-09-01",{"name":75,"class":46},"Riphah International University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":47},"100600980","strength-training-response-of-muscle-in-glp-1-users-100600980","NCT07104539","Strength Training Response of Muscle in GLP-1 Users","STRONG-GLP","Inclusion Criteria:\n\n* Age, 50y+\n* Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less\n* Weight \\\u003C300 lb\n* Pass a health and exercise readiness screening\n\nExclusion Criteria:\n\n* Age \\\u003C50\n* Weight \\>300 lb\n* Osteoporosis\n* Active metabolic, neoplastic, or cardiovascular disease\n* Unable or unwilling to provide consent","50 Years",{"count":85,"type":21},30,[24],"GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance\u002Ffall risk among adults age 50 and older.",[32],[90,91,92,93,94,95],"Weight loss","GLP-1 agonist","Obesity","Lean mass","Body composition","Strength training","2026-01-16",{"date":98,"type":39},"2026-01-21",{"date":100,"type":39},"2025-10-08",{"date":102,"type":21},"2027-05",{"name":104,"class":46},"Virginia Polytechnic Institute and State University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":142},"100617748","the-effects-of-medidrink-platinum-and-fava-bean-protein-hydrolysate-on-fitness-in-an-aged-population-100617748","NCT07322653","The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population","Prospective, Open-Label, Multicenter Study to Characterise the Effects of Co-administration of MediDrink Platinum+ Formula Containing Novel Protein Blend SPR-01 and Fava Bean Protein Hydrolysate on Fitness in an Aged Population","Inclusion Criteria:\n\n* 60 years or older\n* BMI ≤ 25 kg\u002Fm²\n* Malnourished (mini nutritional assessment MNA \\\u003C11\n* Sarcopenic: SARC-F score ≥ 4\n* Capable or oral feeding either alone or assisted\n* Ambulatory (WHO PS\u002FECOG 0-3)\n* Ability to complete questionnaires and self assess health status\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Patient cannot eat orally\n* Acute Infection\n* Proven Intestinal obstruction\n* Co-morbidities requiring a special diet (diabetes, kidney disease etc.)\n* Liver dysfunction\n* Acute or chronic renal failure\n* Uncontrollable nausea or vomiting\n* Use of megestrol acetate or metabolic steroids\n* Dietary supplement use in the last 3 months\n* Known intolerance or allergy to the investigational products\n* Participation in any clinical trial within the last 3 months","60 Years",{"count":114,"type":21},75,[24],"Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia",[118,119,120,32,121,122],"Sarcopenia in Elderly","Malnourished","Protein Supplementation","Physical Function","Strength",[29,124,125,126,127,128,129,130,131],"Peptide Therapeutics","PeptiStrong","MediDrink Platinum","Malnourished Elderly","Physical functioning","MediDrink Platinum+","Clinical Nurtition","Nutritional status","2025-12-22",{"date":134,"type":39},"2026-01-07",{"date":136,"type":39},"2025-09-10",{"date":138,"type":21},"2027-01-02",{"name":140,"class":141},"Nuritas Ltd","INDUSTRY",2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":47},"100611239","protein-supplementation-during-dialysis-prosed-100611239","NCT07237997","Protein Supplementation During Dialysis (PROSED)","Re-examining Nutrition in Dialysis Patients: Nutritional Losses and the Role of Supplementation (Part 2).","PROSED","Inclusion Criteria:\n\n* Age ≥ 18 years (no upper age limit)\n* Patients receiving maintenance dialysis for ≥ three months\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Anticipated live donor kidney transplant and\u002For kidney recovery within the period of sample collection.\n* Anticipated change of dialysis modality within the period of sample collection\n* Severe malnutrition based on either:\n\n  * Renal 7-point Subjective Global Assessment (SGA) scores of 1-2\n  * Global Leadership Initiative Malnutrition (GLIM) Stage 2\n* Protein-losing enteropathy.\n* Persistent nephrotic syndrome with \\>3g\u002Fday urinary protein loss.\n* Active wounds or burns contributing to protein losses as judged by the investigator.\n* Current active acute inflammatory illness (likely to have catabolic effect in the opinion of the investigator).\n* Current malignancy based on recent (\\\u003C12 months) diagnosis and\u002For active treatment for malignancy and\u002For planned treatment for malignancy, excluding non-melanoma skin cancers.\n* Pregnancy (current or planned within duration of study) or breast feeding.\n* People with swallowing difficulties precluding safe ingestion (International Dysphagia Diet Standardization Initiative (IDDSI) level 0 thin fluid).\n* People receiving intradialytic parenteral nutrition or intra-peritoneal amino acids, or any other forms of artificial feeding\n* People prescribed levodopa\n* People who are receiving chronic glucocorticoid therapy (\\>10mg day prednisolone or equivalent for \\>7 days within preceding 90 days).\n* People who are consuming a protein dietary intake above 1.5g protein\u002Fkg\u002Fbody weight.\n* People who, in the opinion of the investigator, will be unable to comply with study protocol requirements.\n* People who are vegan or other religious based dietary restrictions which would prevent them taking the supplement.",{"count":152,"type":21},114,[24],"When a patient has dialysis some nutrients are lost in the process. Nutritional losses include protein, trace elements (i.e. zinc, copper and selenium) and water-soluble vitamins (Vitamins C and B). These nutrients are essential for normal body function, including a good immune system and nutritional status. For example, on average the protein losses during a dialysis session (the process where the blood is cleaned via a machine and special fluid) is equal to 6g of protein\u002Fday (which is the equivalent of the amount of protein in 1 egg). Protein needs for the general population are 0.8g protein per kg of body weight. Because people on dialysis lose protein via the dialysis, it is thought that these people need to eat more protein. Currently, in clinical practice for people receiving dialysis, the guidelines are to aim for 1.1 -1.4g of protein per kg of body weight. However, the research is old and very weak.\n\nDialysis treatments have changed over the past 40 years, and the investigator does not know if the replacement of these nutritional losses is important to how well people do on dialysis and if they have any effect on survival. Previous research is mostly limited to haemodialysis (a type of dialysis that requires a machine which cleans the patients' blood via special filters) and peritoneal dialysis (this is a type of dialysis which happens via the patients' tummy). There is no research on the nutritional supplementation in home HD and nocturnal HD. Our research will investigate if a higher protein provision leads to a reduction is hospital admissions and improved outcomes in patients receiving dialysis.",[156,157,158,159,160,161,162,163,164,32],"Dialysis Patients","Dialysis","Protein Energy Wasting","Protein Intake","High Protein Dietary Intake","Diet","Diet Therapy","Hospitalisation","Muscle Mass and Strength","NOT_YET_RECRUITING","2025-11-14",{"date":168,"type":39},"2025-11-20",{"date":170,"type":21},"2026-01-05",{"date":172,"type":21},"2029-10-30",{"name":174,"class":46},"University of Nottingham",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":47},"100606247","evaluation-of-the-relationship-between-muscle-mass-measured-by-bioelectrical-impedance-analysis-and-the-risk-of-hemorrhagic-events-under-direct-oral-anticoagulants-in-the-elderly-100606247","NCT07173075","Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly","SARCORRHAGED","Inclusion Criteria:\n\n* age of at least 70 years\n* treated with one of the two factor Xa inhibitors used in France: Apixaban, Rivaroxaban.\n* For cases : hemorrhagic event causing hospitalization\n* For controls : free from hemorrhagic events.\n\nExclusion Criteria:\n\n* Failure to obtain a consent form\n* Patient under legal protection (guardianship, curatorship, or legal safeguard)\n* Recurrent bleeding from a pre-existing lesion that has not received specific treatment. For example: unexplored gastrointestinal bleeding, cutaneous bleeding from a cancerous wound with therapeutic abstention.\n* Bleeding caused by high-velocity trauma, surgery, or assault\n* Contraindications to impedance measurement: pacemaker, cardiac defibrillator\n* Elements that may provide erroneous impedance measurement data: bilateral limb amputation, bilateral joint replacements, dialysis.\n* Unable to maintain the supine position.\n* Digestive absorption disorder (celiac disease, short bowel, stoma, etc.)","70 Years",{"count":184,"type":21},110,[24],"This study aims to assess whether reduced muscle mass is associated with an increased risk of bleeding in the elderly receiving direct oral anticoagulant therapy.\n\nThe researchers will compare the muscle mass of patients who experienced a hemorrhage (case) with that of patients who did not (control).\n\nMuscle mass is a key criterion in the assessment of sarcopenia and malnutrition, two conditions frequently associated with aging. Sarcopenia is characterized by a significant loss of muscle mass and strength, while malnutrition is an alteration of nutritional status, often accompanied by sarcopenia, weight loss or a low body mass index (BMI). So at the same time, we want to compare sarcopenia and malnutrition between the two groups (case and control).\n\nCases and controls will benefit from a consultation during which measurements will be taken: weight, height, BMI, calf circumference, impedancemetry, etc. A blood test will be taken to measure anti-Xa activity (drug activity) and any missing analyses.",[188,189,190,32,29,191],"Direct Oral Anticoagulant","Hemmorhage","Elderly","Denutrition",[193,194,195,196,197,198,199,200],"direct oral anticoagulant","hemmorhage","bleeding","elderly","muscle mass","sarcopenia","denutrition","impedancemetry","2025-09-12",{"date":203,"type":39},"2025-09-15",{"date":205,"type":21},"2025-10",{"date":207,"type":21},"2027-10",{"name":209,"class":46},"University Hospital, Clermont-Ferrand",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":226,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":47},"100564641","the-effect-of-the-nutraceutical----epicatechin-on-myosteatosis-in-patients-with-advanced-ckd-100564641","NCT06631820","The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD","The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD: a Pilot Study (EPIC-CKD)","EPIC-CKD","Inclusion Criteria:\n\n* estimated glomerular filtration rate (eGFR) \\\u003C 29 ml\u002Fmin\u002F1.75m2\n* no chronic or acute known liver disease\n* not intended to initiate renal replacement therapy treatment in the next 4 months according to nephrologist clinical judgment\n\nExclusion Criteria:\n\n* signs of active infection\n* acute vasculitis\n* type 1 diabetes\n* use of steroids medication\n* transplanted patients\n* patients with deambulatory impairment (wheelchair users, bed rest)\n* patients on compassionate care for the end of life\n* with advanced neurological disorders\n* with cognitive impairments\n* with active cancer diagnosis\n* participation in another interventional trial.",{"count":219,"type":21},10,[24],"Some foods have components that can prevent and treat some diseases and provide beneficial effects for health. These components naturally occurring in foods are called nutraceuticals. Recently, it was found that Epicatechin, which is a kind of nutraceutical from the Catechin's family naturally occurring in green tea and cocoa, has positive effects on muscle mass and strength of people with chronic diseases.\n\nPeople with chronic kidney disease often present muscle loss and lack of strength that are not easily treated with regular diet and physical activity. We here propose a study where 10 individuals with chronic kidney disease will receive a dose of Epicatechin for 8 weeks and we aim to test if Epicatechin improves general muscle health. Based on what is known, we expect to see an increase in muscle mass and strength.\n\nThe dose of Epicatechin provided (100 mg\u002Fday) is safe, since it is much lower than the dose usually available in supplements. In addition, this is the form naturally present in green tea and cocoa and in similar amounts. Subjects participating in the study will be evaluated for muscle mass and strength three times during the study. Muscle mass and muscle quality will be evaluated by ultrasound and magnetic resonance imaging. The participants will also perform some tests like walking in a corridor and seating and standing from a chair to measure their strength and performance. Adverse side effects will be monitored via telephone, and safety will be assessed by monthly blood tests that will evaluate liver and kidney function. If this study shows that Epicatechin can promote muscle growth and strength, it will positively affect patients with chronic kidney disease that might benefit of a natural substance from food to improve muscle health.",[223,224,225,31,32],"Chronic Kidney Disease(CKD)","Myosteatosis","Mitochondrial Dysfunction",[227,228,229,230,231,232,233],"myosteatosis","epicatechin","nutraceuticals","chronic kidney disease","mitochondrial dysfunction","muscle regeneration","muscle function","2025-07-07",{"date":236,"type":39},"2025-07-10",{"date":238,"type":39},"2025-01-17",{"date":240,"type":21},"2026-10",{"name":242,"class":46},"Karolinska Institutet",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100579800","calf-circumference-adjusted-for-body-composition-to-assess-muscle-mass-100579800","NCT06829004","Calf Circumference Adjusted for Body Composition to Assess Muscle Mass","Inclusion Criteria:\n\nBooked to undergo bone density scanning (DEXA) at Tartu University Hospital\n\nExclusion Criteria:\n\nIsolation for infectious disease Pregnancy and lactation Unable to understand or follow study protocol",{"count":250,"type":21},150,"OBSERVATIONAL","Muscle mass is a critical indicator for malnutrition and sarcopenia assessment. Anthropometric measurements like calf circumference (CC) could be a simple and cost-effective alternative when gold standard methods are not available. However, CC is probably less accurate for estimating muscle mass in female patients and patients with obesity. This study investigates whether adjusting CC using mid-upper arm circumference (MUAC) improves muscle mass estimation in patients with obesity. If validated, this correction method would serve as a simple clinical tool for muscle mass assessment.",[32,254],"Obesity and Overweight","2025-02-10",{"date":257,"type":39},"2025-02-17",{"date":259,"type":21},"2025-02-15",{"date":261,"type":21},"2026-06-30",{"name":263,"class":46},"University of Tartu",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":16,"sex":17,"minAge":112,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":47},"100571380","multicomponent-vs-pilates-on-mass-strength-and-physical-performance-in-older-adults-100571380","NCT06719505","Multicomponent vs Pilates on Mass, Strength, and Physical Performance in Older Adults","Comparison Between a Multicomponent Training Program and Pilates on Muscle Mass, Muscle Strength, and Physical Performance in Older Adults: A Randomized Controlled Trial","versus","Inclusion Criteria:\n\n* Not currently participating in a physical training program for at least six months;\n* No medical restrictions for physical activity and physical tests;\n* Achieve a score of 19 or higher on the Mini-Mental State Examination.\n\nExclusion Criteria:\n\n* Individuals with severe\u002Fdisabling musculoskeletal and\u002For neurological dysfunctions;\n* Neurological disorders or cognitive impairment;\n* Use of supplements for muscle mass increase;\n* History of recent fractures or surgeries and severe cardiorespiratory diseases.","80 Years",{"count":274,"type":21},100,[24],"Introduction: The aging process can result in several physiological changes, such as the loss of muscle mass, muscle strength, and physical performance, collectively defined as sarcopenia. Sarcopenia is considered one of the primary health challenges among older adults. To prevent this condition and improve related health outcomes, regular physical exercise is the most recommended strategy, with multicomponent exercises being particularly effective for older individuals. Pilates is another potential form of physical exercise that has gained popularity among older adults seeking to improve muscle mass, strength, and physical performance. However, significant gaps remain in the literature, with a notable lack of studies evaluating the efficacy of Pilates in improving sarcopenic outcomes. Objective: To compare the efficacy of multicomponent training programs versus Pilates in improving muscle mass, muscle strength, and physical performance in older adults. Methods: A total of 100 older adults aged 60 to 80 years, of both sexes, will be randomized into two intervention groups: the Multicomponent Training Group (n=50) and the Pilates Group (n=50). Evaluations will be conducted at three time points: baseline (before the intervention), mid-treatment (3 months), and post-treatment (6 months). The following instruments will be used: Dual-energy X-ray absorptiometry (DXA) will be used to assess muscle mass. Muscle strength will be evaluated using an isokinetic dynamometer for the lower limbs and a handgrip dynamometer for the upper limbs. Physical performance will be assessed through the Brazilian version of the Short Physical Performance Battery (SPPB), the gait speed test, and the Timed Up and Go (TUG) test. The Feeling Scale will be applied to determine the affective valence of the exercise programs. The Shapiro-Wilk test will be performed to check the normality of the data, Student's t-test or Mann-Whitney U test will be used depending on whether the distribution is parametric or non-parametric, and ANCOVA will be used to compare the groups post-intervention, considering a 95% confidence interval (p\\\u003C0.05). The data will be analyzed using SPSS 25.0 software.",[32,30,278],"Physical Performance",[27,190,280,281,29],"Fragility","Physical exercise","2024-12-09",{"date":284,"type":39},"2024-12-13",{"date":286,"type":21},"2025-05",{"date":288,"type":21},"2026-02",{"name":290,"class":46},"Universidade Estadual do Norte do Parana"]